Vitamin D, Cognition, and Alzheimer's Disease: Observational and Two-Sample Mendelian Randomization Studies.

Aging Alzheimer’s disease cognitive dysfunction databases genetics mendelian randomization analysis observational study vitamin D deficiency

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
27 May 2024
Historique:
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 31 5 2024
Statut: aheadofprint

Résumé

Observational studies have found that vitamin D supplementation is associated with improved cognition. Further, recent Mendelian randomization (MR) studies have shown that higher vitamin D levels, 25(OH)D, may protect against Alzheimer's disease. Thus, it is possible that 25(OH)D may protect against Alzheimer's disease by improving cognition. We assessed this hypothesis, by examining the relationship between 25(OH)D levels and seven cognitive measurements. To mitigate bias from confounding, we performed two-sample MR analyses. We used instruments from three publications: Manousaki et al. (2020), Sutherland et al. (2022), and the Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration (2021). Our observational studies suggested a protective association between 25(OH)D levels and cognitive measures. An increase in the natural log of 25(OH)D by 1 SD was associated with a higher PACC score (BetaPACCscore = 0.06, 95% CI = (0.04-0.08); p = 1.8×10 - 10). However, in the MR analyses, the estimated effect of 25(OH)D on cognitive measures was null. Specifically, per 1 SD increase in genetically estimated natural log of 25(OH)D, the PACC scores remained unchanged in the overall population, (BetaPACCscore = -0.01, 95% CI (-0.06 to 0.03); p = 0.53), and amongst individuals aged over 60 (BetaPACCscore = 0.03, 95% CI (-0.028 to 0.08); p = 0.35). In conclusion, our MR study found no clear evidence to support a protective role of increased 25(OH)D concentrations on cognitive performance in European ancestry individuals. However, our study cannot entirely dismiss the potential beneficial effect on PACC for individuals over the age of 60.

Sections du résumé

Background UNASSIGNED
Observational studies have found that vitamin D supplementation is associated with improved cognition. Further, recent Mendelian randomization (MR) studies have shown that higher vitamin D levels, 25(OH)D, may protect against Alzheimer's disease. Thus, it is possible that 25(OH)D may protect against Alzheimer's disease by improving cognition.
Objective UNASSIGNED
We assessed this hypothesis, by examining the relationship between 25(OH)D levels and seven cognitive measurements.
Methods UNASSIGNED
To mitigate bias from confounding, we performed two-sample MR analyses. We used instruments from three publications: Manousaki et al. (2020), Sutherland et al. (2022), and the Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration (2021).
Results UNASSIGNED
Our observational studies suggested a protective association between 25(OH)D levels and cognitive measures. An increase in the natural log of 25(OH)D by 1 SD was associated with a higher PACC score (BetaPACCscore = 0.06, 95% CI = (0.04-0.08); p = 1.8×10 - 10). However, in the MR analyses, the estimated effect of 25(OH)D on cognitive measures was null. Specifically, per 1 SD increase in genetically estimated natural log of 25(OH)D, the PACC scores remained unchanged in the overall population, (BetaPACCscore = -0.01, 95% CI (-0.06 to 0.03); p = 0.53), and amongst individuals aged over 60 (BetaPACCscore = 0.03, 95% CI (-0.028 to 0.08); p = 0.35).
Conclusions UNASSIGNED
In conclusion, our MR study found no clear evidence to support a protective role of increased 25(OH)D concentrations on cognitive performance in European ancestry individuals. However, our study cannot entirely dismiss the potential beneficial effect on PACC for individuals over the age of 60.

Identifiants

pubmed: 38820015
pii: JAD221223
doi: 10.3233/JAD-221223
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Yann Ilboudo (Y)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Medicine, McGill University, Montreal, QC, Canada.

Satoshi Yoshiji (S)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Medicine, McGill University, Montreal, QC, Canada.
Department of Human Genetics, McGill University, Montréal, QC, Canada.
Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Japan Society for the Promotion of Science, Japan.

Tianyuan Lu (T)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Statistical Sciences, University of Toronto, Toronto, ON, Canada.
Department of Twin Research, King's College London, London, UK.

Guillaume Butler-Laporte (G)

Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada.

Sirui Zhou (S)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Human Genetics, McGill University, Montréal, QC, Canada.

J Brent Richards (JB)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Medicine, McGill University, Montreal, QC, Canada.
Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada.
Department of Twin Research, King's College London, London, UK.
5 Prime Sciences, Montréal, QC, Canada.

Classifications MeSH